Baltic Region's Leading Scientific Event – RSU Research Week 2025 – to Take Place Next Week in Riga, Latvia
RIGA, Latvia, March 19, 2025 (GLOBE NEWSWIRE) -- From 24 to 28 March 2025, Riga Stradiņš University (RSU) will host one of the most significant scientific events in the Baltic region: RSU Research Week 2025. This biennial forum gathers scientists, academics, industry professionals, and policymakers to share cutting-edge research findings, foster interdisciplinary collaboration, and explore innovative solutions for healthcare and society.
The event will commence on 24 March with an , led by RSU Rector and Research Week 2025 President, Prof. Aigars Pētersons, and featuring distinguished guests including President of Latvia, Edgars Rinkēvičs, as well as keynote speakers Dr. Bertalan Meskó, Director of The Medical Futurist Institute, and Prof. Romain Meeusen from Vrije Universiteit Brussel.
RSU Research Week 2025 will open with the 11th International Student Conference on Health and Social Sciences. From 26 to 28 March, five international conferences will take place simultaneously: Knowledge for Use in Practice – focusing on medicine and healthcare, including a special section on Immunology and Neuroimmunology in Research and Clinical Practice, where a group of seven Lithuanian researchers will participate in discussions on the comprehensive study of primary immunodeficiencies and autoimmune diseases.
Society. Health. Welfare. – bringing together researchers, practitioners, and students from six disciplines: public health, psychology, environmental and occupational medicine, health management, social work, and nursing and midwifery. PLACES – an interdisciplinary conference uniting expertise in political science, law, economics, communication, and other social sciences. Innovation and Artificial Intelligence: The Path from Research to Practice will be held, bringing together experts, policy makers, and industry pioneers to explore the AI impact on medicine, healthcare and society.
This year, nearly 1,300 abstracts have been submitted from more than 40 countries, and 60 renowned experts from at least 19 countries—including from the Karolinska Institute, University College London, Amsterdam UMC, and the University of Helsinki—are among the expected guest speakers.
The previous RSU Research Week in 2023 attracted approximately 7,110 participants from 46 countries, both in person and online, reinforcing its international significance. All RSU Research Week 2025 events will be conducted in English and are free of charge.
The live stream of RSU Research Week will be available on the RSU Facebook page and here. However, the event will be held in person at Riga Stradiņš University (Dzirciema iela 16, Riga, LV-1007).
For further information Tīna Sidoroviča, Head of External Communications, Riga Stradiņš University, mobile:. 29267825, tina.sidorovica@rsu.lvSign in to access your portfolio
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Hamilton Spectator
17 minutes ago
- Hamilton Spectator
Positive PoNSTEP Study Results Presented at Consortium of Multiple Sclerosis Centers Annual Meeting
-PoNS Therapeutic Experience Program (PoNSTEP) study demonstrates durable long-term beneficial effects of PoNS Therapy® on gait deficit improvement in people with Multiple Sclerosis- -Presentation of full PoNSTEP study results expanded upon top line data previously reported- NEWTOWN, Pa., June 12, 2025 (GLOBE NEWSWIRE) — Helius Medical Technologies, Inc. (NASDAQ: HSDT), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced that Deborah Backus, PT, Ph.D., FACRM- Vice President of Research and Innovation at Atlanta's Shepard Center presented the positive results from the PoNS Therapeutic Experience Program, or PoNSTEP, study for people with multiple sclerosis (MS) at the 2025 Consortium of Multiple Sclerosis Centers (CMSC) Annual Meeting on May 29 in Pheonix, Arizona. Dr. Backus' presentation highlighted the importance of treatment adherence as a key requirement for achieving a clinically meaningful improvement in gait disability over 14 weeks of therapy and its sustained therapeutic effect well into 6 months after the end of treatment. The study results confirm controlled and real-world clinical evidence of PoNS Therapy's long-term benefits already reported in people with balance deficit due to traumatic brain injury (TBI). 'The results from this study were received with great interest as they provide the first clinical trial evidence of the long-term therapeutic benefits of PoNS Therapy for functional rehabilitation in the MS population,' stated Antonella Favit-Van Pelt, M.D., Ph.D., Helius' Chief Medical Officer. 'We were excited to engage with both US healthcare professionals and Canadian MS specialists and offer additional insights on the body of clinical and mechanistic evidence of PoNS Therapy's effect in MS. We are encouraged by the growing recognition of the importance of PoNS' direct effect on the central nervous system and its targeted mechanism of action as well as how it correlates with a lasting and sustained effect on gait rehabilitation, especially when comparing PoNS Therapy to other interventions limited to peripheral neuromuscular or transcutaneous stimulation.' CMSC attendees were encouraged at Helius' recent successes in obtaining initial reimbursement from federal and private payers and appreciated the Company's relentless effort to engage with health insurance providers, viewing it as a much-needed endeavor to expand access to PoNS Therapy to all people with MS. 'We are excited by the positive conversations had at CMSC regarding both the therapeutic impact of the data presented and the recent announcement of reimbursement from the VA and out of network commercial payers for PoNS,' stated Dane Andreeff, Helius' President and Chief Executive Officer. 'We anticipate that the increase in reimbursement coverage will significantly lower the barrier to prescribe PoNS and allow for greater access to this important therapy.' About PoNS Therapeutic Experience Program (PoNSTEP) The PoNS Therapeutic Experience Program ('PoNSTEP') is a Helius-sponsored, open-label, observational, interventional multi-center outcome research study designed to assess adherence to on-label PoNS Therapy for improvement in gait deficits for patients with multiple sclerosis ('MS') in a real-world clinical setting. The study aims to understand better the relationship between adherence to on label (100-120 minute per day) PoNS Therapy, which combines the PoNS device with physical therapy, and the therapeutic outcome on gait deficit improvement over 14 weeks of study treatment, as measured by changes in the Dynamic Gait Index (DGI) scores. PoNS Therapy is applied in a supervised clinical setting for the first two weeks (Phase 1) and, independently, at home for the remaining 12 weeks (Phase 2). The study also includes a six-month no-treatment follow-up phase aimed at establishing the durability of the therapeutic effect (Phase 3). The primary endpoint of the study is maintenance of gait improvement from the end of supervised therapy (Phase 1) to the end of unsupervised therapy (Phase 2) in relation to the subject's adherence to PoNS Therapy. The secondary endpoints are, among others, maintenance of improvement of gait and balance deficit over a 6-month timeframe and clinical global impression of change. The study was performed at six Centers of Excellence across the United States, including Neurology Center of New England in Foxboro (MA), the Shepherd Center in Atlanta (GA), Montefiore Medical Center ('Montefiore') in NY (NY), Oregon Health & Science University ('OHSU') in Portland (OR), MGH Institute of Health Professions in Boston (MA), NYU Langone Health in NY (NY), and recruited 43 MS participants with gait deficit. About the PoNS Device and PoNS Therapy The Portable Neuromodulation Stimulator ('PoNS') is an innovative, non-implantable, orally applied therapy that delivers neurostimulation through a mouthpiece connected to a controller and it's used, primarily at home, with physical rehabilitation exercise, to improve balance and gait. The PoNS device, which delivers mild electrical impulses to the tongue, is indicated for use in the United States as a short-term treatment of gait deficit due to mild-to-moderate symptoms from MS and is to be used as an adjunct to a supervised therapeutic exercise program in patients 22 years of age and over by prescription only. PoNS has shown effectiveness in treating gait or balance and a significant reduction in the risk of falling in stroke patients in Canada, where it received authorization for sale in three indications: (i) for use as a short-term treatment (14 weeks) of gait deficit due to mild and moderate symptoms from stroke and is to be used in conjunction with physical therapy; (ii) for use as a short-term treatment (14 weeks) of chronic balance deficit due to mild-to-moderate traumatic brain injury ('mmTBI') and is to be used in conjunction with physical therapy; and (iii) for use as a short-term treatment (14 weeks) of gait deficit due to mild and moderate symptoms from MS and is to be used in conjunction with physical therapy. PoNS is also authorized for sale in Australia for short-term use by healthcare professionals as an adjunct to a therapeutic exercise program to improve balance and gait. For more information visit . About Helius Medical Technologies, Inc. Helius Medical Technologies is a leading neurotech company in the medical device field focused on neurologic deficits using orally applied technology platform that amplifies the brain's ability to engage physiologic compensatory mechanisms and promote neuroplasticity, improving the lives of people dealing with neurologic diseases. The Company's first commercial product is the Portable Neuromodulation Stimulator. For more information about the PoNS or Helius Medical Technologies, visit . Cautionary Disclaimer Statement Certain statements in this news release are not based on historical facts and constitute forward-looking statements or forward-looking information within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and Canadian securities laws. All statements other than statements of historical fact included in this news release are forward-looking statements that involve risks and uncertainties. Forward-looking statements are often identified by terms such as 'believe,' 'expect,' 'continue,' 'will,' 'goal,' 'aim' and similar expressions. Such forward-looking statements include, among others, statements regarding future presentation and uses of the PoNSTEP study results, the availability of commercial reimbursement and the uses and effectiveness of PoNS and PoNS Therapy. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those expressed or implied by such statements. Important factors that could cause actual results to differ materially from the Company's expectations include uncertainties associated with the Company's capital requirements to achieve its business objectives, availability of funds, the Company's ability to find additional sources of funding, manufacturing, labor shortage and supply chain risks, including risks related to manufacturing delays, the Company's ability to obtain national Medicare insurance coverage and to obtain a reimbursement code, the Company's ability to continue to build internal commercial infrastructure, secure state distribution licenses, market awareness of the PoNS device, future clinical trials and the clinical development process, the product development process and the FDA regulatory submission review and approval process, other development activities, ongoing government regulation, and other risks detailed from time to time in the 'Risk Factors' section of the Company's Annual Report on Form 10-K for the year ended December 31, 2023, and its other filings with the United States Securities and Exchange Commission and the Canadian securities regulators, which can be obtained from either at or . The reader is cautioned not to place undue reliance on any forward-looking statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company assumes no obligation to update any forward-looking statement or to update the reasons why actual results could differ from such statements except to the extent required by law. Investor Relations Contact Philip Trip Taylor Gilmartin Group investorrelations@
Yahoo
24 minutes ago
- Yahoo
New Prospective Cohort Study Reporting the Efficacy of Arrow™ Chlorhexidine-Impregnated Central Venous Catheters Demonstrates Reduced Infection Rates Among ICU Patients
WAYNE, Pa., June 12, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced findings from a new multinational study reporting efficacy of Arrow™ Chlorhexidine-Impregnated Central Venous Catheters (CVCs). This prospective cohort study included more than 6,670 patients from 12 Intensive care units in eight hospitals across India, Malaysia, Papua New Guinea, Colombia, Egypt and Turkey. Key highlights include: The pre-specified CVC subgroup analysis evaluated the impact of Chlorhexidine-impregnated CVCs on CLABSI rates using CLABSI rates per 1,000 CL (central-line)-days. 70.5% reduction in the incidence of CLABSI in patients with Arrowg+ard Blue™ and Arrowg+ard Blue Plus™ CVCs vs. plain (non-impregnated) catheters. Lower incidence of infection-causing pathogens with Chlorhexidine-impregnated CVCs, including gram-negative and gram-positive bacteria and fungi. Insertion training and the use of maximal barrier precautions were similar across both groups, eliminating technique variability as a confounding factor. Use of an unprotected CVC may be an independent risk factor for CLABSI when compared to patients with Chlorhexidine-impregnated CVCs. The study's CVC analysis demonstrated a statistically significant reduction in CLABSIs of 70.5% in patients receiving the impregnated antimicrobial catheters. These patients had longer average length of ICU stay and device utilization ratios, indicating frequent and extended use. Despite this, infection remained significantly lower, underscoring the potential benefit of the antimicrobial technology even in high-risk patients. Acknowledging potential variations in patients and characteristics across study hospitals and the lack of a metric (e.g., Standard Infection Ratio) to adjust for these factors in the countries in the study, the authors noted that the study data nonetheless provides 'significant evidence' regarding impregnated CVCs. According to Dr. Amy Bardin, Vice President of Clinical and Medical Affairs at Teleflex, this new multinational study suggests that even with proper training and adherence to best practices—including catheter insertion, care, and maximal barrier precautions—unprotected CVCs may be an independent risk factor for CLABSI compared to chlorhexidine-impregnated CVCs. This new research reinforces our performance claims for effectiveness of Arrowg+ard Blue™ and Arrowg+ard Blue Plus™ CVCs against common CLABSI pathogens. The study identified that patients with plain CVCs 'had a higher incidence of gram-negative bacteria, such as Klebsiella pneumoniae, Pseudomonas aeruginosa, Escherichia coli, gram-positive bacteria, such as Staphylococcus aureus, Enterococcus faecium, and fungi, such as Candida species.' The results from this study's Arrowg+ard Blue™ and Arrowg+ard Blue Plus™ CVC subgroup analysis reinforce the effectiveness of Chlorhexidine on Arrow™ CVCs. The full results of this study can be accessed at About Teleflex IncorporatedAs a global provider of medical technologies, Teleflex is driven by our purpose to improve the health and quality of people's lives. Through our vision to become the most trusted partner in healthcare, we offer a diverse portfolio with solutions in the therapy areas of anesthesia, emergency medicine, interventional cardiology and radiology, surgical, vascular access, and urology. We believe that the potential of great people, purpose driven innovation, and world-class products can shape the future direction of healthcare. Teleflex is the home of Arrow™, Barrigel™, Deknatel™, LMA™, Pilling™, QuikClot™, Rüsch™, UroLift™ and Weck™ – trusted brands united by a common sense of purpose. At Teleflex, we are empowering the future of healthcare. For more information, please visit Forward-Looking StatementsAny statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Any forward-looking statements contained herein are based on our management's current beliefs and expectations, but are subject to a number of risks, uncertainties and changes in circumstances, which may cause actual results or company actions to differ materially from what is expressed or implied by these statements. These risks and uncertainties are identified and described in more detail in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K. *The Rosenthal et al. study is referenced for only the pre-specified CVC subgroup analysis, which excludes PICCs (8 of the 6,672 catheters used in the study's overall analysis were PICCs). Arrowg+ard Blue Advance™ PICCs are not indicated for CLABSI reduction. Teleflex funded editorial support but was not involved in data analysis or manuscript content. Reference: Rosenthal VD, Yin R, Jin Z, et al. Multicenter, multinational, prospective cohort study of the impact of chlorhexidine impregnated versus plain central lines on central line-associated bloodstream infections. Am J Infect Control. Published online March 6, 2025. doi:10.1016/ Rx OnlyContraindications:The Arrowg+ard Blue™ and Arrowg+ard Blue Plus™ Catheters are contraindicated for patients with known hypersensitivity to chlorhexidine, silver sulfadiazine and/or sulfa complete indications, contraindications, warnings, precautions, and adverse reactions, please reference each referenced product's full package insert. Teleflex, the Teleflex logo, Arrow, Arrowg+ard Blue, Arrowg+ard Blue Advance, Arrowg+ard Blue Plus, Deknatel, LMA, Pilling, QuikClot, Rusch, UroLift, and Weck are trademarks or registered trademarks of Teleflex Incorporated or its affiliates, in the U.S. and/or other countries. All other marks are the property of their respective owners. © 2025 Teleflex Incorporated. All rights reserved. MC-010846 Contact:Teleflex IncorporatedLawrence KeuschVice President, Investor Relations and Strategy in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Associated Press
25 minutes ago
- Associated Press
Catheter Precision (VTAK) Reports Key Progress for the LockeT Product
FORT MILL, S.C., June 12, 2025 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (VTAK - NYSE/American), a US based medical device company focused on developing technologically advanced products for the cardiac electrophysiology market announced that LockeT sales for Q2 2025 are on track to be the highest to date. Second quarter 2025 LockeT sales are already outpacing Q2 2024 sales with a 200% increase. Catheter Precision now has several US hospitals that are on track to issue more than $100,000 in purchase orders each for LockeT by the end of 2025. These hospitals include Montefiore (Bronx, NY), Eisenhower Health (Rancho Mirage, CA), and Overland Park Regional Medical Center (Overland Park, KS). As previously announced, LockeT received the CE Mark enabling sales in Europe. Catheter Precision has secured a new distributor in Italy and anticipates additional distributors in the coming days for Spain, Portugal and the UK and is actively searching for the right partner is other EU countries. David Jenkins, CEO of Catheter Precision said, 'We are excited about the upcoming activities, sales pipeline and expanded use by existing customer to increase revenue generated by LockeT. At this time, there is a live case scheduled on Monday, Juen 16 with a key opinion leader where he will demonstrate LockeT during an Italian symposium, increasing its awareness to the new market. As a company, we continue to focus on improving product awareness, increasing product usage and expanding our footprint into Europe.' About LockeT Catheter Precision's LockeT is a suture retention device intended to assist in wound closure after percutaneous venous punctures. LockeT is a Class 1 device registered with the FDA and has received CE Mark approval. About Catheter Precision Catheter Precision is an innovative U.S.-based medical device company bringing new solutions to market to improve the treatment of cardiac arrhythmias. It is focused on developing groundbreaking technology for electrophysiology procedures by collaborating with physicians and continuously advancing its products. Cautionary Note Regarding Forward-Looking Statements Statements in this press release may contain 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to substantial risk and uncertainties. Forward-looking statements can be identified by words such as 'believe,' 'anticipate,' 'may,' 'might,' 'can,' 'could,' 'continue,' 'depends,' 'expect,' 'expand,' 'forecast,' 'intend,' 'predict,' 'plan,' 'rely,' 'should,' 'will,' 'may,' 'seek,' or the negative of these terms and other similar expressions, although not all forward-looking statements contain these words. These forward-looking statements include, but are not limited to, statements regarding product evaluations at the hospital, and that the purchase order indicates that the hospital and its staff see the value and benefits that LockeT can bring and expectations regarding LockeT evaluations in the coming weeks. The Company's expectations and beliefs regarding these matters may not materialize. Actual outcomes and results may differ materially from those contemplated by these forward-looking statements as a result of uncertainties, risks and changes in circumstances, including but not limited to risks and uncertainties included under the caption 'Risk Factors' in the Company's Form 10-K filed with the SEC and available at The forward-looking statements included in this communication are made only as of the date hereof. The Company assumes no obligation and does not intend to update these forward-looking statements, except as required by law. CONTACTS: At the Company David Jenkins 973-691-2000 [email protected] # # #
